Source link : https://newshealth.biz/health-news/alzheimers-benefits-may-continue-after-donanemab-treatment-ends-data-suggest/
(MedPage Today) — New data suggested that donanemab (Kisunla) sustained long-term benefits after a limited dosing period in a subgroup of people with early symptomatic Alzheimer’s disease. Early Alzheimer’s patients who completed their course… Source link : https://www.medpagetoday.com/meetingcoverage/ctad/118877 Author : Publish date : 2025-12-07 19:18:00 Copyright for syndicated content belongs to the linked Source.
The post Alzheimer’s Benefits May Continue After Donanemab Treatment Ends, Data Suggest first appeared on News Health.
—-
Author : News Health
Publish date : 2025-12-07 19:18:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8